Forbes J M & Co. LLP Has $319,000 Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Forbes J M & Co. LLP raised its position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 21.9% during the 4th quarter, HoldingsChannel reports. The fund owned 59,000 shares of the company’s stock after buying an additional 10,599 shares during the quarter. Forbes J M & Co. LLP’s holdings in Nuvectis Pharma were worth $319,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Baldwin Wealth Partners LLC MA increased its position in shares of Nuvectis Pharma by 104.4% in the fourth quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock valued at $1,926,000 after acquiring an additional 181,831 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Nuvectis Pharma by 49.8% in the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock valued at $501,000 after buying an additional 26,489 shares during the last quarter. GSA Capital Partners LLP increased its holdings in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after buying an additional 1,790 shares during the last quarter. Nations Financial Group Inc. IA ADV bought a new stake in Nuvectis Pharma during the third quarter worth $63,000. Finally, Iridian Asset Management LLC CT acquired a new stake in Nuvectis Pharma in the third quarter valued at $348,000. 96.77% of the stock is owned by institutional investors.

Insider Transactions at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $4.70 per share, for a total transaction of $79,900.00. Following the purchase, the insider now owns 2,612,000 shares in the company, valued at $12,276,400. This represents a 0.66 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ron Bentsur bought 20,000 shares of Nuvectis Pharma stock in a transaction that occurred on Friday, November 15th. The shares were bought at an average cost of $4.92 per share, with a total value of $98,400.00. Following the acquisition, the chief executive officer now directly owns 3,266,424 shares in the company, valued at $16,070,806.08. This trade represents a 0.62 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 43,500 shares of company stock worth $209,205. 35.78% of the stock is owned by company insiders.

Nuvectis Pharma Stock Performance

Nuvectis Pharma stock opened at $6.71 on Friday. The company’s 50-day moving average is $5.57 and its 200-day moving average is $6.35. Nuvectis Pharma, Inc. has a fifty-two week low of $4.44 and a fifty-two week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same period last year, the company posted ($0.37) EPS. As a group, research analysts predict that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.